



e-therapeutics plc
("e-therapeutics" or "ETX" or the "Company")

Results of Annual General Meeting – 10 July 2025

The Annual General Meeting votes were as follows:

Resolution	Votes For	%	Votes Against	%	Abstentions	Resolution Result
Ordinary Resolution 1	441,378,512	100	0	0.00	164	Passed
Ordinary Resolution 2	441,359,425	100	0	0.00	19,251	Passed
Ordinary Resolution 3	441,347,297	100	0	0.00	31,379	Passed
Ordinary Resolution 4	441,346,297	100	1000	0.00	31,379	Passed
Ordinary Resolution 5	441,359,425	100	0	0.00	19,251	Passed
Ordinary Resolution 6	441,359,425	100	0	0.00	19,251	Passed
Special Resolution 7	441,347,297	100	0	0.00	31,379	Passed

Ordinary Resolution 1	To receive the accounts for the financial year ended 31 January 2025 together with the Directors' Report and the Auditor's Report for that period.
Ordinary Resolution 2	To re-elect Michael Bretherton as a Director of the Company, who has been a Director since 10 February 2020 and was last re-elected by shareholders in July 2022.
Ordinary Resolution 3	To elect Jeremy Punnett as a Director of the company, who was appointed by the Board on 16 July 2024, as Non-Executive Director.
Ordinary Resolution 4	To reappoint Crowe U.K. LLP as the Auditor of the Company.
Ordinary Resolution 5	To authorise the Directors to set the remuneration of the Auditor of the Company.
Ordinary Resolution 6	That the Directors be and are hereby generally and unconditionally authorised for the purposes of Section 551 of the Companies Act 2006 (the "Act") to exercise all the powers of the Company to allot shares and grant rights to subscribe for, or convert any security into, shares.
Special Resolution 7	That, subject to the passing of resolution 6, the Directors be and are hereby authorised pursuant to Section 570(1) of the Act to allot equity securities (as defined in Section 560(1) of the Act) of the Company for cash pursuant to the authorisation conferred by that resolution, as if Section 561 of the Act did not apply to any such allotment, provided that this power shall be limited to the allotment of equity securities for cash.